SCIENTIFIC publications

/cun/en/investigacion/publicaciones-cientificas/areaMain/02
  • Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer

    Corral J (1), Mok TS (2), Nakagawa K (3), Rosell R (4), Lee KH (5), Migliorino MR (6), Pluzanski A (7), Linke R (8), Devgan G (9), Tan W (10), Quinn S (11), Wang T (12), Wu YL (13).

    (1) Clínica Universidad de Navarra, Madrid, 28027, Spain.
    (2) State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, PR China.
    (3) Kindai University Hospital, Osaka, 589-8511, Japan.
    (4) Catalan Institute of Oncology, Barcelona, Spain.
    (5) Chungbuk National University Hospital, Cheongju, Korea.
    (6) Pulmonary Oncology Unit, San Camillo-Forlanini Hospital, Rome, 00152, Italy.
    (7) The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology, Warsaw, 02-781, Poland.
    (8) SFJ Pharmaceuticals®, Pleasanton, CA 94588, USA.
    (9) Pfizer Oncology, New York, NY 10017, USA.
    (10) Pfizer Clinical Pharmacology, San Diego, CA 92121, USA.
    (11) Pfizer Oncology, Cambridge, MA 02139, USA.
    (12) Pfizer Oncology, Groton, CT 06340, USA.
    (13) Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, PR China.

    Future Oncology 17 JULY 2019

  • Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer

    Duruisseaux M (1), Martínez-Cardús A (2), Calleja-Cervantes ME (2), Moran S (2), Castro de Moura M (2), Davalos V (2), Piñeyro D (2), Sanchez-Cespedes M (2), Girard N (3), Brevet M (4), Giroux-Leprieur E (5), Dumenil C (6), Pradotto M (7), Bironzo P (7), Capelletto E (7), Novello S (7), Cortot A (8), Copin MC (9), Karachaliou N (10), Gonzalez-Cao M (11), Peralta S (12), Montuenga LM (13), Gil-Bazo I (14), Baraibar I (15), Lozano MD (16), Varela M (17), Ruffinelli JC (18), Palmero R (18), Nadal E (18), Moran T (19), Perez L (20), Ramos I (21), Xiao Q (22), Fernandez AF (23), Fraga MF (24), Gut M 25, Gut I (25), Teixidó C (26), Vilariño N (27), Prat A (27), Reguart N (27), Benito A (28), Garrido P (29), Barragan I (30), Emile JF (31), Rosell R (32), Brambilla E (33), Esteller M (34)

    (1) Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain; Department of Respiratory Medicine, Groupement Hospitalier Est, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon, France.
    (2) Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain.
    (3) Department of Respiratory Medicine, Groupement Hospitalier Est, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon, France.
    (4) Department of Pathology, Centre de biologie et pathologie Est, Institut de Cancérologie des Hospices Civils de Lyon, Université Lyon 1, Lyon, France.
    (5) Department of Respiratory Diseases and Thoracic Oncology, APHP-Hôpital Ambroise Pare, Boulogne-Billancourt, France; EA4340, UVSQ, University Paris-Saclay, Boulogne-Billancourt, France.
    (6) Department of Respiratory Diseases and Thoracic Oncology, APHP-Hôpital Ambroise Pare, Boulogne-Billancourt, France.
    (7) Department of Oncology, University of Turin, AOU San Luigi, Turin, Italy.
    (8) Thoracic Oncology Department, CHU Lille, University of Lille, Lille, France; UMR 8161-M3T-Mechanisms of Tumorigenesis and Targeted Therapies, CNRS, Institut Pasteur de Lille, University of Lille, Lille, France.
    (9) Department of Pathology, CHU Lille, University of Lille, Lille, France.
    (10) Medical Oncology Service, Institute of Oncology Rosell, University Hospital Sagrat Cor, QuironSalud Group, Barcelona, Spain.
    (11) Medical Oncology Service, Quirón Dexeus University Hospital, Barcelona, Catalonia, Spain.
    (12) Medical Oncology Service, University Hospital Sant Joan de Reus, Reus, Spain.
    (13) Program in Solid Tumors and Biomarkers, Center for Applied Medical Research, Pamplona, Spain; Navarra Health Research Institute, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain.
    (14) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Navarra Health Research Institute, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain.
    (15) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Navarra Health Research Institute, Pamplona, Spain.
    (16) Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain; Navarra Health Research Institute, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain.
    (17) Pathology Department, University Hospital Bellvitge, Barcelona, Spain.
    (18) Medical Oncology Department, Catalan Institute of Oncology, Hospital Duran I Reynals, Barcelona, Spain.
    (19) Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Barcelona, Spain.
    (20) Department of Pathology, Hospitales Universitarios Regional y Virgen de la Victoria, Institute of Biomedical Research in Malaga, University of Málaga, Málaga, Spain.
    (21) Medical Oncology Service, Hospitales Universitarios Regional y Virgen de la Victoria, Institute of Biomedical Research in Malaga, University of Málaga, Málaga, Spain.
    (22) Pharmacoepigenetics Group, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
    (23) Cancer Epigenetics Laboratory, Institute of Oncology of Asturias, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain; Fundación para la Investigación Biosanitaria de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.
    (24) Nanomaterials & Nanotechnology Research Center, Universidad de Oviedo, Oviedo, Spain.
    (25) CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.
    (26) Pathology Department, Hospital Clinic, Institut d'Investigacions Biomédiques August Pi i Sunyer, Barcelona, Spain.
    (27) Medical Oncology Department, Hospital Clinic, Institut d'Investigacions Biomédiques August Pi i Sunyer, Barcelona, Spain.
    (28) Pathology Department, University Hospital Ramon y Cajal, Madrid, Spain.
    (29) Medical Oncology Service, University Hospital Ramon y Cajal, Madrid, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain.
    (30) Medical Oncology Service, Hospitales Universitarios Regional y Virgen de la Victoria, Institute of Biomedical Research in Malaga, University of Málaga, Málaga, Spain; Pharmacoepigenetics Group, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
    (31) Department of Pathology Department, APHP-Hôpital Ambroise Pare, Boulogne-Billancourt, France.
    (32) Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Barcelona, Spain.
    (33) Centre Hospitalier Grenoble, INSERM U1219, University UGA, Grenoble, France.
    (34) Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona, Spain; Institucio Catalana de Recerca i Estudis Avançats, Barcelona, Spain.

    The Lancet. Respiratory Medicine 06 JULY 2019

  • Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer

    Garcia Garcia Y (1), de Juan Ferré A (2), Mendiola C (3), Barretina-Ginesta MP (4), Gaba Garcia L (5), Santaballa Bertrán A (6), Bover Barcelo I (7), Gil-Martin M (8), Manzano A (9), Rubio Pérez MJ (10), Romeo Marin M (11), Arqueros Núñez C (12), García-Martínez E (13), Gonzalez Martin A (14).

    (1) Medical Oncology Department, Parc Taulí Hospital Universitari. Institut d'Investigació iInnovació Parc Taulí I3PT. Universitat Autònoma de Barcelona, Sabadell, Spain
    (2) Medical Oncology Department, University Hospital Marqués de Valdecilla, Santander, Spain.
    (3) Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
    (4 )Medical Oncology Department, Catalan Institute of Oncology, Hospital Universitari Dr Josep Trueta, Girona, Spain.
    (5) Department of Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr Josep Trueta, and Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain.
    (6) Medical Oncology Department, University and Polytechnic Hospital La Fe, Valencia, Spain.
    (7) Medical Oncology Department, Hospital Son Llàtzer, Palma de Mallorca, Spain.
    (8) Medical Oncology Department, Catalan Institute of Oncology-Institut d'Investigació Biomédica de Bellvitge (IDIBELL), Hospital Duran i Reynals, L'Hospitalet-Barcelona, Barcelona, Spain.
    (9) Medical Oncology, Hospital Clinico San Carlos, Madrid, Spain.
    (10) Medical Oncology, University Hospital Reina Sofia, Córdoba, Spain.
    (11) Medical Oncology Department, Catalan Institute of Oncology, Badalona - Institut d'Investigació Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain.
    (12) Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
    (13) Hematology and Medical Oncology Service, University Hospital Morales Meseguer, Murcia, Spain.
    (14) Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.

    International Journal of Gynecological Cancer 01 JULY 2019

  • Early-stage mucinous carcinoma (infiltrative type) of the ovary and fertility preservation

    Platero M (1), Espinosa I (1), Vega Suarez V (2), Gonzalez Martin A (3), Chiva L (4)

    (1) Obstetrics and Gynecology, Clinica Universidad de Navarra, Madrid, Spain.
    (2) Radiology, Clínica Universidad de Navarra, Madrid, Spain.
    (3) Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain.
    (4) Obstetrics and Gynecology, Clinica Universidad de Navarra, Madrid, Spain

    International Journal of Gynecological Cancer 16 APRIL 2019

  • EUSOMA position regarding breast implant associated anaplastic large cell lymphoma

    Cardoso MJ (1), Wyld L (2), Rubio IT (3), Leidenius M (4), Curigliano G (5), Cutuli B (6), Marotti L (7), Biganzoli L (8).

    (1) Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Nova Medical School, Lisbon, Portugal.
    (2) Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
    (3) Breast Surgical Oncology, Clínica Universidad de Navarra, Madrid, Universidad de Navarra, Spain.
    (4 Breast Surgery Unit, Comprehensive Cancer Center Helsinki University Hospital, Madrid, Finland.
    (5) Innovative Therapies Division and New Drug Development Program, Istituto Europeo di Oncologia, Milan, Medical Oncology, University of Milan, Milan, Italy.
    (6) Institut du Cancer Courlancy, Reims, France.
    (7) EUSOMA, Florence, Italy.
    (8) Breast Unit, Nuovo Ospedale di Prato, Prato, Italy.

    Breast 26 JANUARY 2019

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra